MilliporeSigma has bolstered its messenger RNA (mRNA) manufacturing offering with the addition of German CDMO AmpTec and its polymerase chain reaction (PCR)-based technology.
The deal, financials of which have not been divulged, went through last week and plays into MilliporeSIgmaâ€™s strategy to expand its mRNA manufacturing services for both therapeutic modalities and diagnostics.
The â€śtechnology acquisition,â€ť as MilliporeSigma spokeswoman Rachel Bloom-Baglin describes the deal, comes fresh on the arrival of the first two mRNA vaccines. The US FDA approved both Pfizer/BioNTechâ€™s and Modernaâ€™s COVID-19 vaccines last month, and rollout has already begun in the US and elsewhere.
â€śThe success of mRNA-based vaccines for COVID-19 lays the path to accelerate the development of these therapies for many other diseases,â€ť said Bloom-Baglin. â€śThis acquisition expands our capabilities to develop and manufacture mRNA for our customers to use for vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases.â€ť
â€śBy combining AmpTecâ€™s PCR-based technology with our 20+ years of expertise in lipid manufacturing, we will be able to expand our mRNA capabilities and provide a truly integrated offering across the mRNA manufacturing process, which in turn will help advance life-enhancing therapeutics.â€ť
The Hamburg, Germany-based AmpTec brings its polymerase chain reaction (PCR)-based technology to MilliporeSigmaâ€™s offering. According to the firm, the tech offers advantages over other manufacturing platforms in homogeneity, purity, activity and flexibility.
â€śIn addition to specializing in mRNA technology, AmpTec also has a diagnostics business, which focuses on producing customized long RNAs and DNAs for in vitro diagnostics,â€ť Bloom-Baglin told us. â€śThis will complement our diagnostics business, which specializes in providing critical raw materials, components and services for in vitro diagnostics manufacturers.â€ť
For example, AmpTec offers synthetic nucleic acids for the COVID-19 diagnostics tool EURM-019, released in April last year to facilitate quality control of the detection of SARS-CoV-2 at core facilities and hospital laboratories.